Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists

Pituitary. 2007;10(1):81-6. doi: 10.1007/s11102-007-0014-1.

Abstract

Prolactinomas are common tumors of the anterior pituitary gland. While conventional therapies, including dopamine agonists, transsphenoidal surgery and radiotherapy, are usually effective in controlling tumor growth, some patients develop treatment-resistant tumors. In this report, we describe a patient with an invasive prolactinoma resistant to conventional therapy that responded to the administration of the alkylating agent, temozolomide.

Publication types

  • Case Reports

MeSH terms

  • Dacarbazine / adverse effects
  • Dacarbazine / analogs & derivatives*
  • Dacarbazine / therapeutic use
  • Dopamine Agonists / therapeutic use*
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Middle Aged
  • Pituitary Neoplasms / diagnosis
  • Pituitary Neoplasms / drug therapy*
  • Prolactin / blood
  • Prolactinoma / diagnosis
  • Prolactinoma / drug therapy*
  • Temozolomide

Substances

  • Dopamine Agonists
  • Dacarbazine
  • Prolactin
  • Temozolomide